Targeting the $5 BILLION Soft Tissue Repair Market

Chitogenx is in the regulatory lead for regenerative products

Sponsored
Chitogenx Inc. Profile

 

 

 

 

HOW BIG IS THE SOFT TISSUE REPAIR MARKET?

US$5bn MARKET OPPORTUNITY

 

Rotator Cuff TEAR

 

Leads to shoulder dysfunction and pain

4M patients US alone

  600K annual surgeries US alone

$600M+ market opportunity

 

Meniscus Tear Repair

 

Painful, compromises knee function

1.2M surgeries annually US alone

$1B+ market opporunity

 

Cartilage Lesions Repair

 

Lesions cause friction and pain

1.2M detected lesions annually US alone

120K surgeries (lack of options)

$1B+ market opportunity

 

 

 

 



 

CHITOGENX INC. ANNOUNCES ENROLLMENT OF FIRST PATIENT IN ITS U.S. PHASE I/II ROTATOR CUFF TEAR REPAIR CLINICAL TRIAL

  • The first patient surgery was successfully completed at the Tucson Orthopaedic Institute in Tucson, Arizona.
  • The ORTHO-R Phase I/II clinical study is a prospective, randomized, controlled, and blinded clinical trial, to evaluate the safety and efficacy of ORTHO-R as an adjunct to standard of care surgery vs. standard of care surgery alone for rotator cuff tear repair.
  • The clinical trial will enroll a total of 78 patients at 10 clinical sites throughout the U.S.

 

ORTHO REGENERATIVE TECHNOLOGIES REPORTS ITS FIRST QUARTER 2023 RESULTS

 

      Patients recruitment initiated for U.S. Phase I/II rotator cuff tear repair clinical trial in June 2023

      Phase I/II clinical trial IND application cleared by FDA for testing ORTHO-R in combination with PRP for rotator cuff tear repair

      ORTHO-R / PRP combination becomes the first drug/biologic implant combination product cleared by the FDA for clinical trial testing

      Key U.S., Canadian and European composition and method patent secured for ORTHO-R / PRP soft tissue repair platform, protecting core IP until 2035

      $3.2 Million over-subscribed private placement secured in Q1-2022

      $500,000 grant secured to advance the development of second technology platform indication, ORTHO-M, for meniscus repair

 

CHITOGENX INC. INITIATES PATIENTS RECRUITMENT FOR ITS U.S. PHASE I/II ROTATOR CUFF TEAR REPAIR CLINICAL TRIAL

  • Contracting procedures completed for 6 of the 10 clinical trial sites
  • 5 sites fully activated, with ongoing patients' screening and recruitment

 

CHITOGENX INC. RECEIVES $500,000 AXELYS GRANT TO ADVANCE ORTHO-M DEVELOPMENT FOR MENISCUS REPAIR

  • Meniscus indication confirms proprietary technology platform multi-indications potential
  • Grant to accelerate development of second clinical indication

 

STANDARD OF CARE SURGERY HAS HIGH FAILURE RATE

 

HENCE THE STRONG NEED FOR MORE EFFECTIVE TREATMENTS

ORTHO-R® TECHNOLOGY – NEW PARADIGM

ORTHO-R EASY TO USE AND ADDS 8-10 MINUTES TO STANDARD OF CARE SURGERY

BENEFITS

-       Increases PRP residence time for faster & better tissue repair (from less than 24 hours for PRP alone to up to 6 weeks for Ortho-R product)

-       Keeps voluminous implant completely covering the surgically repaired site

-       Easy to use by orthopedic surgeons

-       Better mechanical and biological new tissue properties and faster recovery

-       Better tissue formation and integration between tendon and bone

-       Safe and gradual and sustain release of growth factors and cytokines from platelets

 

PRODUCT DEVELOPMENT PORTFOLIO

 

KEY VALUE MILESTONES

HANUMAN PRP SYSTEM GLOBAL LICENSING DEAL

 

-       Exclusive Global License to use, manufacture, sublicense and sell Product in combination with ORTHO-R

-       Fields: Tendons, Ligaments, Meniscus, Cartilage and Wound Healing (non-exclusive)

-       Royalty to Hanuman on net sales (on Product)

-       New product addition to ORTHO RTI portfolio

-       Generates significant revenues to ORTHO RTI in surplus of ORTHO R product

-       Perfect complementarity / integration to ORTHO-R

 

 

WORLD CLASS PARTNERSHIPS AND COLLABORATORS

 

 

  

Chitogenx Signs Memorandum Of Understanding With California Medical Innovations Institute 

  • This Memorandum, between CALMI2 and ChitogenX will identify collaborative projects and pursue proof of concept research programs utilizing ChitogenX's proprietary regenerative medicine solutions to improve patient outcomes.

  • Dr. Kassab's group has obtained nearly $100M worth of extramural research grants to fund scientific medical developments

 

 

Last changed at 18-Nov-2022 04:30PM by AGORACOM-Multimedia